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Summary
The aim of this study was to evaluate the long-term efficacy
and tolerability of the 3-hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase inhibitor simvastatin, over a 24-
week period. Patients (108) with primary hypercholesterol-
aemia were clinically, haematologically and biochemically
evaluated and established on a cholesterol-lowering diet.
After a wash-out period free from other lipid-lowering drugs
and a baseline period on placebo of 1 month each, 10 mg
simvastatin was introduced at night. The dose was increased
to 20 mg and 40 mg at 6 and 12 weeks' follow-up respectively
if the total cholesterol (TC) level was still above 5,17 mmolll.
Follow-up took place every 6 weeks and included lipid,
haematological, biochemical and clinical evaluation. A full
ophthalmological evaluation was conducted at baseline and
at 24 weeks' follow-up.
Overall the TC level was reduced below the baseline level
by 34,3% at week 18 of follow-up and 32,5% at week 24.
Patients with higher initial TC levels showed greater TC
lowering in response to simvastatin than did those with lower
initial TC levels. A group of 45 patients was followed up for
an additional 12 weeks after the end of the trial and maintained
TC reductions similar to those at the end of the trial.
Fourteen patients experienced adverse effects which were
thought to be drug-related. One patient was withdrawn from
the trial after developing conjunctivitis that proved to be
related to the use of simvastatin. The rest of the adverse
experiences were not severe enough to terminate the use of
simvastatin and included gastro-intestinal tract symptoms,
dizziness, conjunctivitis, pruritus and the aggravation of
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eczema. Aspartate aminotransferase, alanine aminotransferase
and crea!ine kinase values were raised in a significant number
of patients but no patient was withdrawn from the trial. A
dose of 40 mg simvastatin was associated with a rise in the
abovementioned enzymes more often than were lower doses.
S AIr Med J 1991; 79: 639-645.
The benefit of reducing raised plasma cholesterol levels to
prevent myocardial infarction (MI) has been illustrated by a
number of large multicentre drug trialS. I,3 These results led to
the formulation of general guidelines for the diagnosis and
management of hypercholesterolaemia4- 6 in order to reduce
coronary heart disease (CHD) in a number of countries.
Most persons with a cholesterol level imparting moderate or
even high risk4- 6 of developing CHD can reduce that level by
means of a strict cholesterol-lowering diet and other lifestyle
modifications. A significant number of persons will, however,
still require medication to achieve optimal cholesterol levels.
Currently available drugs employed to reduce plasma
cholesterol levels show limited efficacy and are associated with
troublesome side-effects, while long-term safety cannot be
assured for all drugs. 7 A new group of cholesterol-lowering
drugs appear to be promising for the treatment of hyper-
cholesterolaemia, as has been shown by controlled and uncon-
trolled trials. 8- 15 These drugs inhibit the rate-limiting enzyme
3-hydroxy-3-methylglutaryl-eoenzyme A (HMG-CoA) reduc-
tase, in the synthesis of cholesterol. When de novo cholesterol
synthesis is reduced, the hepatocyte increases its expression of
low-density lipoprotein (LDL) receptors in order to meet the
demand for cholesterol. Consequently plasma LDL cholesterol
(LDLC) is reduced. Low doses of these drugs will reduce
plasma cholesterol effectively, and in shon-term studies they
seem to be safe.8- n Consequently in 1987 the Food and Drug
Administration in the USA approved. the use of the HMG-
CoA reductase inhibitor lovastatin for the treatment of hyper-
cholesterolaemia. A number of other HMG-CoA reductase
inhibitors are currently under investigation for the treatment
of this condition.
The aim of this study was to investigate whether the efficacy
and tolerability of the HMG-CoA reductase inhibitor simvasta-
tin during shon-term studies is maintained in a once-a-day




One hundred and seventeen patients with primary hyper-
cholesterolaemia, aged 18 - 65 years and with a s~rum total
cholesterol (TC) level above 6,5 mmol/l, were selected at five
South African lipid clinics to participate" in the study. Exclusion
criteria were a plasma triglyceride level above 4,7 mmoVl or
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Fig. 2. Shift in the distribution of TC levels at baseline and 6, 12,
18 and 24 weeks of follow-up.
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Statistical methods
The univariate distribution of each management was studied
to detect data recording errors as well as to assess differences
between centres. Sequential differences between the same
measurement at the different times of follow-up were calculated
for each variable and separately for each centr~, to study the
changes from visit to visit. The Fisher method of combining
the significance levels of independent statistical tests was
applied to accommodate any heterogeneity in the distributions
for the different centres. This method was used to combine
separate statistical tests done on the TC and LDLC results
from each centre. 19
In Figs 2 and 3 the 'box' part of the plot of the TC
measurement is an arrangement· of three parallel lines, the
bottom, middle and upper lines representing the lower quartile
(25th percentile), the median (50th percentile) and the upper
quartile (75th percentile) respectively. The mean is indicated
by a + sign, which is usually inside the 'box'. The mean and
the median are about the same if the distribution is symmetri-
cal. The spread of the distribution can be measured by the
distance between the upper and lower quartiles, this distance
being called the interquartile distance.
In Fig. 4 a bivariate plot of baseline LDLC and LDLC at 6,
18 and 24 weeks' follow-up respectively is provided. The line
15
The ophthalmological examination included a visual acuity
.test and a slit-lamp examination after dilatation of the pupil.
Blood for biochemical and haematological analyses was taken
after a 12-hour overnight fast. The non-lipid biochemical and
haematological measurements were performed using standard
techniques by routine clinical chemistry and haematological
laboratories. These analyses included the measurement of
haemoglobin, haematocrit, white blood cells, differential and
platelet counts, and total bilirubin, alkaline phosphatase,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatine kinase (CK), creatinine and glucose levels.
Cholesterol and triglyceride determinations were done using
enzymatic methods. All centres used the same commercial
analytical kits and methods ·to obtain comparable results. For
TC determinations the CHOL-PAP-HPR enzymatic kit
(Boehringer Mannheim) was used and· for triglyceride deter-
minations the neutral fat kit, also from Boehringer Mannheim,
was used. High-density lipoprotein cholesterol (HDLC) was
measured after precipitation of the apoprotein-eontaining lipo-
proteins by heparin-manganese chloride according to the Lipid
Research Clinics protocolY LDLC was calculated using





Fig. 1. Drug regimen.
Clinical and laboratory monitoring
Adherence to treatment was assessed by tablet counts at
each visit. Any side-effects were monitored and reported to
the drug company as they occurred. The patients continued
with whatever non-lipid lowering medication they had been
taking before commencing simvastatin and any additional
drugs taken were noted. The pulse, blood pressure and body
weight were measured at each visit. If any change in lifestyle
took place, it was noted. At the [mal visit an ECG and
physical and ophthalmological examinations were conducted
by the same person who had conducted the initial examination.
Treatment was initiated with 10 mg .simvastatin to be taken
with the evening meal. After 6 weeks a complete laboratory
evaluation was done. If the TC level was still 5,17 mmoVl or
above the simvastatin dose was increased to 20 mg in the
evening. For patients in whom it was 5,17 mmoVl or above 12
w:eeks after the initial treatment, the dose was increased to 40
mg in the evening. At 18 weeks cholestyramine could be added
to the regimen if the TC level was still above 5,17 mmoVl.
Subjects were monitored at 6-week intervals until each had
taken simvastatin for a period of 6 months.
In addition, the dose of individual patients was adapted in
response to side-effects experienced and the degree of choles-
terollowering achieved.
Treatment regimen
Fig. 1 represents a flow-diagram of the drug regimen. All
patients who had been on lipid-lowering drugs before the trial
discontinued these drugs for a wash-out period of at least 4
weeks. This was followed by a 4-week baseline period on
placebo before the start of aCtive treatrilent. At entry, 8 weeks
before the initiation of simvastatin, participants were placed
on a lipid-lowering diet as prescribed by the Nutrition Com-
mittee of the American Heart Association. 16 The patients were
seen by a dietitian at each visit to the clinic to assess diet
compliance.
types I, IV or V hyperlipidaemias, and a fasting glucose level
above 7,7 mmoVl; pregnant or lactating women, as well as
premenopausal women who were not on effective contraception
during the study, persons with a history of drug or alcohol
abuse, impaired hepatic function or a history of hepatitis,
patients who had had a partial ileal bypass, who had recently
suffered from unstable angina or an MI, or had had coronary
bypass surgery within the previous 3 months; patients who
used immunosuppressive drugs were also excluded.
All participants underwent clinical examination and labora-
tory investigations; electrocardiography and a detailed eye
examination, including slit-lamp examination by an ophthal-
mologist after dilatation of the pupil, as well as visu31 acuity
testing, were also performed.
All participants gave voluntary written consent to participate
in the study after a detailed explanation of the protocol and
potential risks of the trial. The protocol was approved by the
ethical and research committees of the universities involved.




























Baseline total cholesterol level (mrnol/ll of three groups
Fig. 3. Comparison of the reduction of TC levels in three groups
of patients on the basis of their initial TC levels.
"
of no change in LDLC levels from baseline to follow-up
period is indicated by a solid diagonal line. A lowering of
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TABLE I. THE CHARACTERISTICS OF PATIENTS IN
THE TRIAL
Data for 108 of the 117 patients entered into the trial (mean
age 45,3 years, range 21 - 63 years, 56 men and 52 women)
were analysed (2 patients were excluded because they were
outside the age range, mean triglyceride levels for 3 patients
were above 4,7 mmoVl before taking the drug, mean serum
cholesterol levels for 2 patients were below 6,5 mmoVl. before
taking the drug, 1 patient's laboratory results could not be
verified, and 1 patient was lost to follow-up after taking 10 mg
simvastatin for 6 weeks). The characteristics of the patients

















Fig. 4. Comparison of baseline LDLC levels with LDLC levels at 6
weeks (10 mg simvastatin) (top), 18 weeks (40 mg) (middle) and











Age (yrs) (mean) (range 21 - 63 years)
Males (%)
Patients with a history of CHD (%)*
Patients with ECG features of CHD (%)t
Patients with clinical signs of
hypercholesterolaemia (%)t
Patients with possible familial
hypercholesterolaemia (%),
.. CHD was considered to be present jf a patient reported suffering from angina
and/or myocardial infarction and/or had had coronary artery bypass surgery.
ECG changes considered were Q waves and S-T segment depression.
; Clinical signs of hypercholesterolaemia considered were tendon xanthomas.
arcus cornealis and xanthelasma
Patients with familial hypercholesterolaemia had a total cholesterol level in the
high CHD risk category (> 80th percentile)' and a triglyceride level below 2
mmol/l as well as clinical signs of hypercholesterolaemia.
Of the 108 patients who participated in the trial, 93 followed
the same dosage panern over the study period (4 patients
followed the same dosage panern except for the last period, a
further 4 stayed on a 20 mg dose for the third period and
caught up again at the last period, 4 never moved on to a
higher dose than 20 mg, and the remaining 3 received 10, 10,
20 and 20 mg at the four consecutive visits).
The change in the distribution of TC during the use of
simvastatin is shown in Fig. 2. The mean TC level (± SD) of
the two baseline determinations (TC levd before and after
placebo period) was 9,4 ± 1,75 mmoll1. On a dose of 10 mg
simvastatin the mean TC level was reduced to 7,17 ± 1,42
mmoVI, a statistically significant 23,8% reduction. At the 12th
week of follow-up the dose for 104 patients was increased to
20 mg and a further reduction to a mean TC level of 6,78 ±
1,16 mmoVl was observed. Six patients' TC levels were below
5,17 mmoVI.
At the 18th week of follow-up the dose for 93 patients was
increased to 40 mg simvastatin. The mean TC level. was
reduced to 6,2 ± 1,25 mmoVl. Twenty-three patients' TC
levels were reduced to below 5,17 mmol/l. Three patients
whose TC levels fell below 4,5 mmoVl on 40 mg simvastatin
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had the dose reduced to 20 mg, while in 1 patient the dose was
reduced to 30 mg because of side-effects. Nine patients at one
centre also received cholestyramine in addition to 40 mg
simvastatin at week 18 of follow-up.
At the 24th week of follow-up the mean TC level of the
patients increased slightly to 6,35 ± 1,23 mmoVl. In only 16
patients was the TC level below 5,17 mmoVl. The addition of
cholestyramine at the one centre did not have any observable
lowering effects on TC. The mean TC level of the 9 patients
given cholestyramine was 8,04 mmoVl before taking the drug
and 8;02 mmoVl 6 weeks after its commencement. Overall the
mean TC level was reduced by 34,3% at week 18 of follow-up
and by 32,5% at week 24. A differing degree of TC lowering in
response to simvastatin was found at the five participating
centres. At week 18 of follow-up the lowering of TC from
baseline at the five centres was 23%, 34,6%, 35,4%, 37,2% and
37,3% respectively and at week 24 it was 19,7%,33,2%,34,7%
35%, and 35,6%.
As there was a slight increase in the TC level at week 24 of
follow-up the possibility of an 'escape phenomenon' was con-
sidered. To establish whether this had occurred 49 participants
who remained on a constant simvastatin dose were followed up
for a further 12 weeks after the trial had ended. No significant
change in the TC level occurred.
When the degree of TC lowering on simvastatin was com-
pared with the initial TC level by means of the general
additive int<;ractive modepo to fit a representative line, it was
found that the patients with the higher TC levels showed a
greater degree of TC lowering in response to simvastatin than
patients with lower initial TC levels. This is illustrated in Fig.
3, where the mean TC reduction of patients with a baseline
TC of below 7,5 mmoVl was 2 mmoVl while taking 10 mg
simvastatin (week 6 of follow-up). On the same dose patients
with an initial TC level equal or above 10 mmoVl showed a
mean TC reduction of 3 mmoVl. This phenomenon was
observed at all the follow-up visits and at all the various doses
of simvastatin used. The subgroup of patients with familial
hypercholesterolaemia, who had a higher initial TC level than
the rest of the cohott, did not show this phenomenon of
greater TC lowering than the rest of the cohott.
Fig. 4 shows the overall shift of LDLC levels of all partici-
pants at weeks 6, 18 and 24 of follow-up. Mean LDLC was
reduced by 28%, 32,7%, 39,8% and 38,6% compared with
baseline at weeks 6, 12, 18 and 24 on simvastatin treatment.
Overall, serum HDLCand triglyceride levels we~e not
affected by simvastatin. The responses of these two lipid
fractions to simvastatin were significantly different between
the five centres and could therefore not be combined.
Adverse experiences
During the course of the trial no"significant changes or
trends were observed in pulse, blood pressure or body weight
recordings or in the results ofoph~ologicalexamination of
the participating patients.
Table 11 indicates the clinical adverse experiences reported
by patients during the trial as well as those side-effects
attributed by investigators as possibly, probably and definitely
related to taking simvastatin. ReJ'Qrted clinical adverse
experiences cover many body systems, with the most common
ones being mild gastro-intestinal symptoms, manifestations of
CHD, joint pains, skin conditions and eye complaints.
The conditions thought to be related to simvastatin were a
variety of gastro-intestinal complaints (10 participants), skin
conditions (3), dizziness (1), and conjunctivitis (1).
The gastro-intestinal conditions reported were nausea, heart-
burn, abdominal discomfort, flatulence, constipation and loose
stools. Many of these complaints were p-ansient or relieved by
taking divided or reduced doses of simyastatin or by ensuring
that the drug was taken after meals.
The skin conditions thought to be related to simvastatin
were pruritus, bruising and the aggravation of mild eczema to
the point that topical steroid treatment was required.
One patient complained of dizziness and concomitant nausea
when the simvastatin dose was increased. Divided doses allowed
a gradual increase to 30 mg simvastatin. This patient's symp-
toms persisted at a dose of 40 mg, which had to be reduced to
30 mg. At the end of the trial the symptoms recurred and
treatment was terminated.
One patient complained of conjunctivitis. The patient
developed redness and itchiness of the eyes after taking 40 mg
simvastatin for 22 days (total time on the drug was 14 weeks
and 1 day). Withdrawal of the drug cleared symptoms in 3
days. Rechallenging the patient with the drug on two occasions
precipitated the same symptoms after 3 days and 24 hours
respectively. The patient was withdrawn from the trial.
Seven patients suffered serious adverse cardiovascular
effects during the trial. None of these was thought to be
related to the use of simvastatin. Six of these patients had a
history of CHD before entering the trial. Three patients
suffered angina during the trial, 2 patients developed crescendo
angina necessitating coronary artery bypass grafts, and 2
patients were found to have an ECG pattern of inferior MI (Q
waves in leads 11, III and AVF). One of these patients was
admitted to the coronary unit on day 24 on a dose of 10 mg
simvastatin. Angioplasty was performed and he was symptom-
free from the 10th week of the trial. T):J.e second patient, with
an ECG pattern of inferior MI at week 24, had"no previous
history of CHD and suffered no signs or symptoms suggestive
of MI during the course of the trial.
With the exception of the liver enzymes and CK, no signifi-
cant trends were found in the haematological or "biochemical
measurements on the blood samples of the patients during
simvastatin treatment. Two patients became hyperuricaemic
and 2 patients maintained a raised urate level throughout the
trial. One patient, who was a regular blood donor, developed
hypochromic anaemia and 1 patient developed thrombocyto-
penia during the course of the drug trial.
The plasma serum enzyme levels were analysed with respect
to the normal laboratory range for each centre. The AST
levels were raised in 7,2%, 4,1%, 2,1% and 5,2% of participants
at 6, 12, 18 and 24 weeks follow-up. A rise in the ALT level in
5,2%, 10,3% and 14,6% of participants was observed at 6, 12,
18 and 24 weeks of follow-up. CK levels rose in 7,2%, 2,1%,
10,3% and 5,2% of participants above the upper limit of
normal at the same periods of follow-up. In 6 of these patients
the raised CK level was. associated with high levels of physical
activity. In all cases these enzyme levels had been normal after
the wash-out period.
No participant was withdrawn from the trial due to a
threefold or greater increase in AST, ALTor CK. For ALT
in particular, and to a lesser degree for AST and CK, a
tendency to higher levels within the normal range of values for
a given centre was observed at all centres. This was more
marked in patients on a 40 mg!d dose of simvastatin than in
patients at lower doses.
Discussion
The degree ofTC (34,3%) and LDLC (39,8%) lowering in this
trial is consistent with other rers>rted results on the use of
simvastatin2l-23 and 10vastatin.24- 8 At baseline 90,9% of parti-
cipating patients were in the high CHD risk category because
of their TC levels,4 while at the end of the trial only 24,2% fell
into this category. Such reductions in TC and LDLC levels
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statin and cholestyramine, reducing the fraction of simvastatin
absorbed. This may also happen if simvastatin or any active
metabolite undergoes enterohepatic recycling.
Simvastatin was tolerated very well in this study (Table 11).
Only 1 patient withdrew from the study. She suffered from
conjunctivitis, which was clearly induced by simvastatin, as
was indicated on two occasions by rechallenge. Other adverse
experiences ascribed to simvastatin were a variety of gastro-
intestinal symptoms, some transient, while others were relieved
by divided or reduced doses of simvastatin. Dizziness and
aggravation of eczema were also observed in this study. Some
adverse ~riences reported in other simvastatin and lovastatin
trialS/ I - 23, 9 such as headache and blurred vision, were not
experienced by patients in this trial.
As in other reported studies/ I - 29 increases in hepatic trahs-
aminases, particularly serum glutamate pyruvate transaminase,
were observed. These increases were small and did not lead to
any participants being withdrawn from the trial. Similar
findings have been reported for most other lipid-lowering
drugs. 7 The long-term effect that the continued use of simva-
statin has on the liver when transaminase levels are elevated is
not known. For this reason patients taking simvastatin should
have their hepatic function monitored at regular intervals.
Consideration should be given to discontinuing the drug if the
increase is persistent. In this study higher doses of simvastatin
were associated with greater increases in these enzymes as was
observed with the lower 10 mg dose.
Although no patients complained of muscle pain or weakness,
10 patients were found to have raised CK values; 6 of them
reported participating in regular heavy physical exercise. No
patient on simvastatin had clinical manifestations of rhabdo-
myolysis. In view of reports of rhabdomyolysis in patients
taking lovastatin3O-32 in combination with gemfIbrozil, niacin
and cyclosporin, CK levels in patients on simvastatin should
be monitored carefully and symptoms of muscle dysfunction
should be sought.
When lovastatin was administered to a variety of experimental
animals in doses greatly exceeding those used for human
therapy, cataracts developed. 33 However, ophthalmological
examinations formed an important part of this and other
trials. 10,34 To date no data published or results from this study
indicate any effect of lovastatin or simvastatin on the human
lens,8,29 but annual slit-lamp examinations are none the less
recommended by the drug manufacturers.
We found that a daily dose of 10 mg simvastatin reduced
the TC level by 23,5% and the LDLC level by 28%. Mol et
al. 22 reported similar reductions (24,8% for TC and 27,2% for
LDLC) on the same dose. Berger et al. 23 pointed out that a
dose of 20 mg lovastatin was required to reduce TC levels by
25% and LDLC levels by 30% in most studies. In contrast,
these results show that only 10 mg simvastatin is required to
reduce TC and LDLC by a similar margin to that achieved by
20 mg lovastatin. The findings of Illingworth et al. 35 also
suggest that simvastatin may be more effective than lovastatin
in reducing TC. This could possibly be explained by the fact
that simvastatin has an affinity for HMG-CoA reductase that
is 13 000 times more than that of the natural substrate, while
the affinity of lovastatin is only half (6 250) that of simvastatin.8
This possibie relationship between affinities for the enzyme
and clinical potency may have a bearing on adverse effects
related to these drugs. In this study the adverse effects,
particularly those on hepatic transaminases, were found to
occur more commonly at higher doses.
The design of the present stUdy has limitations in that it was
not a randomised controlled trial and therefore effects ascribed
to the use of simvastatin could be questioned. In other
randomised controlled trials with simvastatin ll - 15,20 and
lovastatin34-37 similar effects to the ones ·reported in this study
could be shown to be associated with the use of these drugs.
Simvastatin represents a promising new HMG-CoA reduc-
tase inhibitor that reduces TC and LDLC levels. Few adverse
effects were reported for the duration of this study, and for
most patients a single dose after the evening meal was sufficient
to achieve a substantial lowering of cholesterol levels, which
may lower CHD risk. Possible detrimental side-effects of
lifelong use of simvastatin still need to be determined.
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Does whole-cell pertussis vaccine protect
black South African infants?
Assessment of post-vaccination events and antibody responses to
pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3
A. RAMKISSOON, H. M. COOVADIA, W. E. K. LOENING, M. NDLOVANA
Summary
The whole-cell pertussis vaccine currently used in South
Africa has not been adequately evaluated for post-vaccination
events and immunogenicity. A trial of this vaccine combined
with diphtheria and tetanus toxoids (DTP) was undertaken in
115 black babies who received primary vaccination at 2, 4
and 6 months of age. Serological IgG responses to the major
antigens of Bordetella pertussis, filamentous haemagglutinin
(FHA), pertussis toxin (PT) and fimbriae (agglutinogens 2 and
3 (AGG 2 + 3), were evaluated by enzyme-linked
immunosorbent assay in sera obtained at birth, and before
vaccination at 2,4 and 6 months and at 9 months. Surprisingly,
after 3 doses of DTP, responses to PT and FHA were found
merely to restore levels of IgG to PT and FHA to those found
in cord blood. In contrast with the positive increases in these
antibodies found in other series of whole-cell vaccination, the
anti-PT seroconversion rate was only 19% and the anti-FHA
rate only 24%. High levels of anti-AGG 2 + 3 were produced
with 67,2% seroconversion.
The frequency and nature of post-vaccination events were
recorded. Incidences of all reactions to the vaccine were low
(7,6%): Fever (3,2%) and excessive crying (2,4%) were the
most frequenUy occurring minor events. The rate of neuro-
logical post-vaccination events (without sequelae) during the
brief follow-up period was 2 hypotonic-hyporesponsive
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episodes (8,03/1 000 doses) and 1 convulsion (4,02/1000
doses).
Significant pertussis antibody levels were found in maternal
and cord sera with levels in the latter frequently being higher.
Three cases of pertussis occurred during the study period.
Only 1 of the subjects had completed primary vaccination. In
view of these findings, the need for a proper efficacy and
safety study of the currently used DTP vaccine is urgently
indicated in South Africa.
S Atr Med J 1991; 79: 645·649.
Penussis (whooping cough) remains a major cause of morbidity
and mortality in the very young. According to World Health
Organisation estimates, 60000 deaths due to penussis occur
yearly in Africa, vinually all in unvaccinated infants. 1
Conventional whole-cell penussis vaccines at present used
in most parts of the world consist of inactivated cells of
Bordecella percussis and are therefore a mixture of antigens,
some of which, while essential for protection, also produce
adverse reactions. These are considered the most reactive of
childhood vaccines used in routine vaccination schedules,
although the possible contribution of the diphtheria and tetanus
components of triple vaccines is frequently ignored. Whole-
cell vaccines are associated with a wide range of side-effects,
which include local and systemic reactions and some tempo-
rally associated neurological disorders. 2 Use of the vaccine was
discontinued, for example, in Japan after the sudden death of
recently vaccinated infants and in Sweden where protection
after vaccination with unabsorbed vaccine was poor and side-
effects unacceptable.
The safety and efficacy of whole-cell penussis vaccines have
been the subject of discussion in medical publications for the
past decade. Efficacy rates ranging from 20% to 95% have been
